Venture Catalysts Fully Exits Pee Safe With 9.6X Return
The result underscores Venture Catalysts’ patient early-stage strategy validated by Pee Safe’s scale-up.
Overview
- The exit was completed during Pee Safe’s $32 million Series C led by OrbiMed in January 2026.
- The 2017 pre-Series investment delivered a 30.53% XIRR for the fund’s limited partners.
- Pee Safe now sells through more than 50,000 retail touch points across over 100 Indian cities after broadening beyond toilet hygiene into femtech and personal care.
- FY25 filings show operating revenue up 44% year over year to ₹82.4 crore, with net loss narrowed to about ₹4 crore.
- The company has raised over $45 million to date, while Venture Catalysts recently secured ₹150 crore in fresh capital.